A competition for radical ideas in the fight against blindness will move to its next phase by challenging participants to build functioning human retina prototypes. The National Eye Institute (NEI) 3-D Retina Organoid Challenge (NEI 3-D ROC 2020) is a $1-million federal prize competition designed to generate lab-grown human retinas from stem cells. Organoids developed for the competition will mimic the structure, organization, and function of the human retina, the light-sensitive tissue in the back of the eye.
The recent approval of two novel medications for glaucoma – the first new medications for the disorder in nearly 18 years – are fruit borne from decades of foundational scientific research supported by the National Eye Institute (NEI). The two medications, Vyzulta and Rhopressa, treat elevated eye pressure. High intraocular pressure is a causal risk factor for primary open-angle glaucoma, the most common form of glaucoma and a leading cause of vision loss and blindness in the U.S. and worldwide.
Common, unavoidable eye movements may be a cause of glaucoma in people with normal intraocular pressure (normal-tension glaucoma), according to new research supported by the National Eye Institute.